Replies to post #6838 on Halozyme Therapeutics Inc (HALO)

[maumar]

I haven't read those reports and I am not sure. JPM has a $50 Dec 22 target. Perhaps the more bullish analysts expect the conversion rate for Darzalex FasPro to get to 95% and that would keep royalties growing hopefully at 30% in 2022 and 2023, then some royalties from Efgartigimod in 2024. They must think there will be some new deals with a decent amount of milestone payments and in some cases, hopefully Darzalex especially, there will be coformulation patents. Tecentriq and Opdivo should get approved in 2024, perhaps Ocrevus would be next. This is the best case scenario, I think.

But if we get no new deals in the next six months and Darzalex starts having more serious competition, I fear those price targets will get lowered.